General Information of Drug (ID: DMIU1HY)

Drug Name
HuM-195-Ac-225 Drug Info
Synonyms HuM-195 [225Ac]; SMART 225Ac-M195; Actinium-225-M195; SMART actinium-225-M195; Actinium-225-HuM-195; 225Ac-HuM-195; 225Ac-lintuzumab
Indication
Disease Entry ICD 11 Status REF
Acute myelogenous leukaemia 2A41 Phase 1/2 [1]
Acute myeloid leukaemia 2A60 Phase 1/2 [2]
Cross-matching ID
TTD Drug ID
DMIU1HY

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Myeloid cell surface antigen CD33 (CD33) TTJVYO3 CD33_HUMAN Inhibitor [3]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Myeloid cell surface antigen CD33 (CD33) DTT CD33 2.485 2.744 2.868 2.744
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Acute myelogenous leukaemia
ICD Disease Classification 2A41
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Myeloid cell surface antigen CD33 (CD33) DTT CD33 5.37E-13 0.58 1.13
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 Clinical pipeline report, company report or official report of Actinium Pharmaceuticals.
3 J Clin Oncol 29: 2011 (suppl; abstr 6516).